Introduction
Over 170 million people are infected with the hepatitis C virus (HCV) worldwide.
However, a significant proportion of acutely infected individuals are able to spontaneously clear the virus, indicating that acquisition of at least partial protective immunity against HCV persistence is possible (1) (2) (3) (4) (5) . Moreover, spontaneous clearance of HCV is associated with a broad and durable HCV-specific proliferative CD4+ T cell response (6) (7) (8) (9) . In contrast, HCV-specific CD4+ T cell responses are rarely detected in chronically infected persons and are usually weak and narrow in breadth (9) (10) (11) . The reasons for the diminished T helper response in chronic HCV infection are unclear, but multiple mechanisms have been suggested including a failure to prime responses, an immunosuppressive effect of HCV proteins on T cells, and exhaustion of HCV-specific T cells by persistently high antigen levels (3, (12) (13) (14) (15) . Elucidating the mechanisms of this diminished T helper response may be critical to the development of a therapeutic HCV vaccine.
Six distinct HCV genotypes and multiple subtypes have been identified that demonstrate up to 50% cross genotype nucleotide divergence (16) . Therefore, a major challenge in the development of an effective vaccine will be to render protective immunity to all of the different HCV genotypes (17) . The degree of possible HCV cross-protective immunity against homologous or heterologous HCV strains has been addressed in a number of observational and experimental studies both in humans (2, 5, (18) (19) (20) (21) and chimpanzees (22) (23) (24) (25) (26) . Some of these studies demonstrate a relative lack of protection against rechallenge with heterologous virus strains, indicating poor cross-genotype recognition (23) .
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Multiple studies have shown that a subgroup of chronically infected subjects, typically those infected with genotypes other than GT1, can display rather broad and vigorous Thelper cell responses targeting GT1-derived antigens (27, 28) . The role of these responses (27) (28) (29) , and their contribution to viral control or the favorable outcome of antiviral therapy in certain genotypes (30) remains unclear. It is equally unclear whether the persistent CD4+ T cell responses to HCV antigens in some chronically infected subjects with non-GT1 infection is due to an altered pathobiology or immunogenicity of these HCV strains, and whether these responses actually target the current, persistent virus.
Recent reports show serological and cellular evidence of prior exposure to heterologous HCV strains in some chronically infected subjects (31, 32) with vigorous CD4+ T cell proliferative responses against HCV GT1 proteins. Therefore, the detection of stronger proliferative responses against GT1a antigens observed in chronic non-GT1 subjects may indicate a previous exposure and clearance of GT1 infection in these persons (33). It has been suggested that these responses are not cross-reactive to the autologous persisting virus, but data supporting this hypothesis are limited.
In this study we analyzed HCV-specific CD4+ T cell responses at the single epitope level in a large cohort of subjects chronically infected with different HCV genotypes, and examined these individuals for serologic evidence of previous infection with heterologous HCV genotypes. We also determined the ability of the HCV-specific CD4+
T cell responses to recognize circulating autologous virus. The cellular, serological, and HCV sequence data presented here suggest that the persistent HCV-specific CD4+ T cell only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From responses detected in a subset of chronically infected patients are unable to recognize the contemporary circulating viruses, but most likely represent immunological scars from a previously resolved HCV infection. The data also highlight that HCV viremia per se is not immunosuppressive for HCV-specific CD4+ T cells (32), but rather that chronic viremia leads to selective elimination of adaptive CD4 responses to the epitopes presented in vivo.
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Materials and Methods
Study subjects. This study was approved by the Institutional Review Board of the Massachusetts General Hospital or the Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro, Brazil, and all subjects gave written informed consent upon enrollment. All subjects -with the exception of C38, C39 who were recruited in Brazil-were recruited in Boston, were naïve for anti-HCV treatment, and had been confirmed anti-HCV positive by thirdgeneration enzyme immunoassay. HCV RNA was measured by the Roche Amplicor Monitor assay (detection limit of 600 IU of HCV RNA per ml plasma). All subjects were HCV RNA positive for at least 24 months. HCV RNA-positive patients were tested for HCV genotype by INNOLIPA (Innogenetics, Ghent, Belgium). Additionally, a 1.2 kb fragment in NS5B of the HCV genome was PCR amplified, sequenced and then compared to genotype reference sequences from the Los Alamos HCV database (34) by phylogenetic analysis using the neighbor joining method. Twenty two subjects with spontaneously resolved HCV infection (previously published in detail (10)) and ten unexposed, seronegative subjects served as control groups.
HCV serotyping. HCV serotypes were determined using the Murex HCV Serotyping 1-6 assay (Abbott, Wiesbaden, Germany) according to the manufacturer's instructions and as previously published (10, 31, 32) . Briefly, immunoplates were coated with synthetic peptides representing variable regions within NS4 from HCV types 1-6. Serum dilutions were then added in the presence of competing peptide in free solution to block crossreactivity.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From HCV peptides and recombinant HCV proteins. Peptides were synthesized corresponding to the amino acid sequences of the HCV-1a strain HCV-1 (GenBank accession number: M62321). A total of 301 20mers overlapping by 10aa and spanning the entire polyprotein were used for screening responses (11) . Additional peptides were synthesized according to autologous viral sequences. Recombinant HCV proteins used in this study were expressed as carboxy-terminal fusion proteins with human superoxide dismutase in Saccharomyces cerevisiae or Escherichia coli and were kindly provided by Michael Houghton (Chiron Corporation, Emeryville, CA). These proteins were derived from the HCV-1 sequence and encoded core (C22-3 aa2 to 120), NS3 (C33C aa1192 to 1457), NS4 (C100.3 aa1569 to 1931), NS3/NS4 (C200 aa1192 to 1931), and NS5 (NS5 aa2054 to 2995).
Sequencing of autologous Virus. Viral RNA was extracted from plasma using the vRNA extraction kit (QIAGEN, Santa Clarita, Ca). Genotype-specific primers were designed based on alignments of all available sequences from public HCV Databases (http://euhcvdb.ibcp.fr/euHCVdb/, http://hcv.lanl.gov/content/hcv-db/index) Using the QIAGEN One-Step RT-PCR kit, RT-PCR cycling conditions were as follows: 50°C for 60 min and 95°C for 15 min, followed by 35 cycles of 30 s at 94°C, 30 s at 54°C, 1.5 min at 72°C, and a final extension of 68°C for 20 min. Nested PCR conditions were 35 cycles of 30 s at 94°C, 30 s at 62°C, 1 min at 72°C, and a final extension of 68°C for 20 min using Titanium Taq DNA polymerase; (CLONTECH Laboratories, Inc., Palo Alto, CA) as previously described (35). PCR fragments were gel or PCR purified (QIAGEN QIAquick Gel extraction / PCR purification kit) and the population sequenced Lymphocyte proliferation assays. Lymphocyte proliferation assays were performed as described previously using c22.3, c33c, c100.3, C200 and NS5 HCV proteins (Chiron) at concentrations of 10 µg/ml (11) .
Bulk stimulation of PBMC. Twenty million fresh or thawed PBMC were depleted of CD8+ cells with magnetic beads according to the manufacturer's instructions (111-47D CD8 Dynal beads, Invitrogen, Carlsbad, CA). The CD8+-depleted cells were stimulated with 1 µg/ml of recombinant HCV antigens (either C22-3, C33C, C100.3, C200 or NS5) in 2 ml of R10/50 medium (RPMI 1640 medium, 10 mM HEPES with 2 mM glutamine and antibiotics (penicillin-streptomycin, 50 U/ml) and 10% fetal calf serum (Sigma Aldrich, St. Louis, MO) supplemented with recombinant interleukin-2 (rIL-2) (50 U/ml)) (11) . Alternatively, for the regions of the HCV genome for which recombinant antigens were not available (E1, E2, p7, and NS2) PBMC were stimulated with overlapping 20-only.
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Elispot assay. Elispot assays were performed as previously described (10, 38) .
Responses were considered positive if the number of spots was three times greater than the background; phytohemagglutinin served as a positive control. All positive responses were reconfirmed by intracellular cytokine assay following stimulation with the specific peptide.
Intracellular IFN-γ staining by flow cytometry. Intracellular cytokine staining (ICS) was performed as previously described (10, 38) . Cells were analyzed on a FACS-Calibur flow cytometer using CELL Quest software (Becton Dickinson). Single peptides that elicited distinct responses of more than three times background IFN-γ production were considered positive.
Statistical analysis
Nonparametric Mann-Whitney U tests were performed using GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA). To avoid overestimation of the total breadth of antiviral responses, responses to adjacent overlapping peptides were counted as responses to 1 epitopic region, with only the stronger response shown. 
Results

CD4+
T cell lines from chronically infected non-GT1 infected subjects show broadly directed responses against GT1a peptides. Forty-four treatment naïve subjects, 24 subjects with chronic HCV GT1 infection and 20 subjects with chronic HCV non-GT1 infection ( Table 1) , were recruited and HCV-specific CD4+ T cell responses to were determined at the single epitope level. There were no significant differences between GT1 and non-GT1 subjects with respect to risk factor for the acquisition of infection (>50% IVDU) or other clinical parameters such as viral HCV RNA titers ( Table 1 ).
The HCV-specific lymphocyte proliferative responses against the HCV proteins were absent in the majority of the chronically infected 37 subjects (18 GT1 /19 non-GT1) for whom lymphoproliferative assays with fresh PBMC could be performed for each of the recombinant HCV proteins. Proliferative responses were more readily detected in persons with non-GT1 infection. None of the 18 subjects with GT1 infection and 6/19 of the non-GT1 subjects displayed significant proliferative responses (stimulation index (SI) above 5) to one or more of the nonstructural proteins (p<0.03) ( Table 1 ). Our findings are in accordance with lymphoproliferative results published by other groups (27, 28, 32) . A representative plot of a chronically non GT1 infected subject with strong proliferative HCV-specific responses is shown in Figure 1a . The responses in subject C35 were stable over one year of follow up despite persistent GT2b viremia greater than 500,000 IU of HCV RNA per ml plasma. In addition, there was no significant alteration in the response at later time points following a sustained virological response after standard 24 week therapy with PEG IFN-α and ribavirin (Figure 1b) . In order to characterize all of the epitopes targeted, a high-resolution screening for HCVspecific T-helper responses was conducted in all of the 44 chronic subjects by antigen specific polyclonal expansion of CD4+ T cells in the presence of rIL-2 (10, 11). These lines were tested using IFN-γ Elispot with pools of HCV GT-1-peptides spanning the entire HCV polyprotein. Responses to single 20mer peptides were then confirmed by intracellular cytokine staining for IFN-γ production. Only in 3/24 subjects with GT1 infection we could detect one or more CD4+ responses compared to 10/20 of the patients with non-GT1 infection (p<0.01), despite the fact that we conducted these screens using GT1a peptides. Altogether, we detected significantly more HCV CD4+ T cell responses in subjects with chronic non-GT1 infection compared to subjects with GT1 infection (non-GT1 subjects: mean 4.2 reponses range 0-25, GT1 subjects: mean 0.2 responses, range 0-3 p=0.0173) (Figure 2a and Table 1) . A maximum of 3 responses were identified in chronically GT1 infected subjects, whereas up to 25 responses were detected in one of the subjects with non-GT1 infection (subject C35, see Table 1 ). Overall we detected 89 responses against 67 different peptide specificities/epitopes in 13 patients of our cohort of 44 chronically infected patients. These responses were broadly distributed across all of the HCV structural and non-structural proteins ( Table 2 ). The majority of these CD4+ specificities have previously been described in subjects with spontaneously resolved infection and, therefore, are not unique to chronic HCV infection. These responses were stably maintained in several patients that were studied sequentially for up to 6 years of chronic untreated infection (data not shown).
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From While the HCV-specific CD4+ T cell responses detected in this cohort with chronic HCV infection have also been described in subjects with resolved infection, we noticed the relative paucity of responses to a group of previously described, dominant, promiscuous, and highly conserved HCV-specific epitopes characteristic of subjects with spontaneously resolved HCV (10, 39, 40) . For example peptide P177 (aa1771-1790), which is targeted by a majority of persons with spontaneously resolved HCV infection (10, 39, 41), was not detected in a single subject with chronic infection irrespective of the genotype. While these dominant epitopes in resolved infection are typically located in relatively conserved areas of the HCV genome, many of the responses detected in the chronically infected subjects with non-GT1 infection were located in regions of high sequence variability among the different genotypes. For example peptides P21 (aa211-230) and P26 (aa261-280), both located in the extremely variable region of E1, were each detected in three subjects with chronic non-GT 1 infection ( Table 2 ).
There is significant disparity between autologous virus sequence and GT1a based peptides. Persistent HCV infection is typically associated with a limited or absent HCVspecific CD4+ response. It was therefore surprising that in a subset of persons with chronic non-GT1 HCV infection we were able to detect up to 25 HCV CD4+ specificities despite high levels of viremia. Since the number of HCV CD4+ specificities detected in short term cell lines did not correlate with lower viral load in the group of non-GT1 patients ( Table 1 , chi square x=0.05), we probed whether these responses targeted the circulating virus sequence as an indication of their ability to contribute to viral control.
To investigate this relationship, we generated autologous sequence data by bulk only.
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Autologous sequence was available for 4/5 of these responses and this sequence did not differ signifcantly from the reference GT1a peptide sequence ( Table 3) . For seven subjects in the group with chronic GT1a infection, autologous sequences for the entire polyprotein were available. This enabled us to compare not only autologous virus in regions where we detected responses, but also to take a detailed look at regions that are commonly targeted in spontaneously resolved HCV infection that were not targeted in the GT1 patients in our cohort. Analysis of autologous sequences in these subjects showed nearly complete conservation in the regions of the three most frequently detected epitopes in spontanously resolved infection (10), P124(aa1241-1260), P177(aa1771-1790), and P257(aa2571-2590) ( Table 4) . None of the 7 subjects showed evidence of escape mutations in these three epitopes at this chronic stage of infection.
In contrast to the 5 CD4+ responses detected in the group of GT1 patients, we detected a total of 84 responses in our 20 subjects with chronic non-GT1 infection. For five non-GT1 patients, autologous sequence was generated using genotype-specific primers (GT2, GT3 or GT4, respectively). Table 3 displays the sequences of all the epitopes for which autologous sequence was available. These sequences are aligned to the GT1a peptide sequence that was used to screen these individuals. In each case, the GT1 sequences targeted by these CD4+ responses differed substantially from the autologous viral sequence. Importantly, these sequences were representative of the identified currently only.
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In order to rule out possible mixed genotype infections in the non-GT1 infected subjects we attempted to amplify virus in the NS5 region using GT1-specific primers in two subjects, C29 and C35. No amplification was noted in either of these subjects suggesting the absence of a possible mixed infection.
Broad HCV-specific CD4+ responses are detectable in non-GT1 subjects with serological evidence of prior exposure to GT1 virus. In this study, we detected a greater number of GT1-specific responses in chronic non-GT1 patients, which is a departure from our previous observations in subjects with resolved HCV infection (10).
In those studies, an average of approximately 10 epitopes targeted by CD4+T cells were detectable in short-term cell lines isolated from subjects with resolved HCV infection (10) . Genotype-specific sub-analysis of the data from that study (10) showed that slightly fewer responses (8 vs 14 p<0.05) were detected in the subjects who had spontaneously resolved a non-GT1 HCV infection as compared to patients with serological indication for clearance of a GT1 virus ( Figure 2B ). Since our screening is performed with GT1 peptides, these data suggest that in persons with resolved infection more responses are missed in subjects with resolved non-GT1 infection, likely due to the greater degree of HCV sequence variation between the autologous sequence and the prototype sequence of our reagents. However, in the chronically infected subjects studied here we found the only.
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The above data suggest that these chronically infected subjects, who are at high risk for repeated HCV exposure due to injection drug use, might have residual responses to a previously cleared infection with a hetreogenous genotype virus. Therefore, in order to determine whether a prior exposure to (and clearance of) GT1 HCV might explain the detection of durable CD4+ T cell responses in chronically non-GT1 infected subjects, we tested for serological evidence of prior exposure to different HCV genotypes by typing sera of the entire cohort with a commercially available Elisa assay (Murex, Cambridge, UK) for genotype 1-6-specific HCV antibodies (31, 32) ( Table 1) .
HCV serotypes were successfully defined in 39 of the 44 subjects in our cohort. In agreement with recent results observed by other groups (32), we found serological evidence of exposure to GT1 in 4 of 19 non-GT 1 infected patients, but there was no evidence of previous exposure to a non-GT1 virus in the 19 GT1 infected subjects.
Serological detection of GT1 in the non-GT1 infected subjects significantly correlated (p=0.0003) with the number of CD4+ responses detected in our comprehensive expansion experiments. These subjects had on average 11 (range 5-25) responses, which was comparable to the number of responses detected in subjects with spontaneously resolved GT1 infection (Figure 3) . Additionally, subject C41 (chronically infected with HCV GT3) had serological evidence of a previous exposure to GT2. After exclusion of subjects in whom we had detected serological evidence of exposure to heterologous
strains, analysis revealed that responses in the remaining 14 subjects were not significantly greater than in chronically infected GT1 subjects (p=0.1).
Further analysis of the pattern of cellular responses in the four non-GT1 subjects that had serological evidence of previous exposure to GT1 virus revealed that while these subjects mounted similar numbers of CD4+ responses as subjects with spontaneously resolved GT1 infection, there was a significant difference in the epitope repertoire. Previously, we described a group of six CD4+ epitopes that are highly conserved between the different HCV genotypes and were frequently targeted by subjects with spontaneously resolved HCV infection (10) . In contrast, those conserved epitopes were much less frequently targeted by subjects with persistent non-GT1 infection which had serological evidence for exposure to GT1. On average, more than two of these six epitopes were detectable in each subject of a previously published cohort of 22 individuals with spontaneously resolved HCV (54 responses in total). In contrast, we detected an average of less than one of these epitopes (three in total) in the 4 non-GT1 subjects mentioned above (2.5 vs. 0.8, p<0.001). These data indicate that only CD4+ responses with a recognition pattern limited to GT1 infection, but not those responses that showed cross-reactivity with other genotypes (including the persistent autologous virus), were maintained in these four subjects.
Memory HCV GT1-specific CD4+ T-cell responses are not cross-reactive with circulating non-GT1 virus. In order to elucidate whether the HCV-specific CD4+ responses that we detected using recombinant HCV proteins and peptides based on GT1a
sequence would recognize autologous circulating virus, we generated peptides based on autologous sequence in three non-GT1 subjects (C29, C30, and C35) and compared the cellular responses to these peptides.
In subject C29, a 49 year old male and former IVD user with chronic GT4 infection and serological evidence of exposure to a GT1 strain, we compared the peptide sequence of all five of the different GT1a peptides that had reproducibly elicited strong responses at different time points in short term lines ( Table 2) . The GT1a peptides, but not peptides representing autologous viral sequences, lead to expansion of peptide-specific T-cells in vitro (Figure 4 a, b) . In addition, none of the five T-cell lines that were established with the GT1-specific peptides cross-reacted with peptides representing the circulating autologous virus in a ICS assay (Figure 4c) . Similar results were obtained for subject C35, who was infected with GT2b but in whom we also detected a serological response to GT1. In ex vivo Elispot experiments we observed strong ex vivo CD4+ responses against GT1a peptide P158 (aa1581-1600) and P180 (aa1881-1900) in PBMC of this individual, and we confirmed that these GT1 based peptides elicited a much stronger response than peptides based on autologous GT2b sequence (Figure 4d) .
These results diverge from observations in subject C30, a female with no history of IVDU with chronic GT4 infection and no serological evidence of a heterologous HCV serotype. Cellular assays showed that the autologous variant of the only HCV CD4+ epitope detected in this subject was equally well recognized as the GT1 peptide (data not shown). The reason for persistence of this single response that we could confirm ex vivo only.
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In order to confirm the lack of cross-genotype recognition of the autologous non-GT1 peptide in patients whose responses were primed with GT1 virus, we tested the cellular responses against two well defined HCV-specific CD4+ cell epitopes, P227 (aa2271-2290) and P158 (aa1581-1600) (10) . Here, we used HCV-specific cell lines from two HLA matched subjects with spontaneously (and serologically defined) resolved GT1 infection, resolver R1 and R23. Peptides representing GT1 sequence were recognized in both subjects with resolved infection while the autologous non-GT1 peptide variants of C29 and C35 respectively failed to induce a response ( Figure 5 ). These data further support the hypothesis that the responses detected in subjects C29 and C35 (with chronic non-GTI infection) were indeed primed by GT1 strains and that these responses do not cross-react with the respective circulating virus.
Discussion
CD4+ T helper cell responses play a key role in the control of viral infections (43-51),
and sustained HCV-specific CD4+ proliferative responses have consistently been demonstrated for spontaneous resolution of acute HCV infection (6, (52) (53) (54) . In contrast, HCV-specific CD4+ responses are usually narrowly directed or undetectable in chronically infected persons (9, 10, 14, 55). However, individual case reports and studies have described strong proliferative HCV-specific responses in individual subjects with only.
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Previously, it was suggested that such responses were induced by previously resolved infections with other HCV strains and the responses detected might not be cross-reactive to the persisting virus in those subjects, but this hypothesis remained to be rigorously tested. The current study was specifically designed to analyze the CD4+ T-cell response against HCV in its full breadth at the single epitope level in a larger cohort, thus allowing a detailed assessment of individual responses and their reactivity against autologous virus as well as the reference GT1 strain.
We observed significantly more HCV-specific CD4+ T cell responses in chronically infected subjects with non-GT1 infection than in subjects with GT1 infection when comparing the number of CD4+ epitopes targeted in each individual. Further sequence analysis of the circulating HCV genomes in non-GT1 patients who displayed significant responses against GT1-derived peptides revealed that the targeted epitopes were not present in vivo. Notably, we found autologous sequences that were distinct from the HCV GT1 prototype sequence of the targeted epitopes and autologous sequences did not have a close phylogenetic relationship to the GT1 sequence ( We observed a lack of cross-genotype reactivity between the T cells and the circulating virus in these subjects, using HCV-peptide-specific T cell lines. Most importantly, 74%
(66/89) of the responses detected in this cohort screened with GT1 peptides were detected in non-GT1 subjects in whom serological evidence of previous exposure to a heterologous HCV strains could be documented (GT1 in 4/5 of cases). In additional experiments, cell lines were generated using GT1-specific and autologous non-GT1 peptides. We confirmed the lack of cross-genotype recognition using these lines by demonstrating that the elicited responses were indeed type-specific. Taken together, the results of these experiments argue against the suggestion of strain-specific suppression of responses in chronically infected subjects (32). However, they do provide further support for the hypothesis that responses detected in this subset of non-GT1 infected patients were primed by prior exposure to a GT1 virus and are ineffective with regards to the non-GT 1 virus persistently infecting those subjects.
Animal models of HCV infection show that protective immunity to homologous virus challenge can be induced after spontaneous resolution of acute infection (2) . In contrast, there is good evidence that this acquired immunity is not fully protective against heterologous genotypes (23, 25) . Here, we provide further evidence for relative lack of cross protective immunity in individuals chronically infected with GT 2, 3 or 4 virus who each show serological and cellular evidence of previous exposure to a heterologous strain. Together, these data demonstrate that re-infection by a heterologous HCV genotype is possible particularly in populations like IVDU with a high risk for multiple exposures (33). In dengue virus infection, another flavivirus, the concept of antigenic sin is believed to be important in understanding viral pathogenesis and the severe clinical complications that arise upon secondary infection with a different genotype dengue strain. This secondary viral encounter is believed to lead to the expansion of previously primed partly crossreactive cells that have a sub optimal avidity for the current virus and thereby interfere with the kinetics and quality of the cellular antiviral response (56) (57) (58) (59) . In the case of reinfection with a heterologous HCV genotype we hypothesize that any HCV cross genotype reactive HCV specific CD4 response exhausts over time while responses against subdominant GT1 epitopes with a high degree of cross-genotype variance are still detectable in these subjects with non-GT1 viremia. The exact pre-requisites of crossprotective immunity will only be understood by prospectively monitoring and studying the viral sequence and immune responses of sequential acute episodes in the chimp model or in high risk populations. Only then will it be possible to determine whether the cellular responses primed by one HCV strain may be partially protective or detrimental to the clearance of a heterologous virus (31).
Unfortunately, we cannot reconstruct the exact timeline of exposure to viruses of different genotypes in this study. Based upon the broad GT1-specific CD4+ T cell responses we detected in these subjects, and the known epidemiological prevalence of HCV infection the US, these data are most consistent with these individuals having cleared a prior GT1 infection and then facing subsequent exposure to a non-GT1 strain.
We cannot rule out, however, the possibility that a subset of subjects in this cohort were only.
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Interestingly, three of the non-GT1 subjects, C29, C35, and C42, which have been described here in detail as having cellular and/or serological responses specific to GT1, expressed the HLA molecules DR1 or DR11. Both of these HLA class II DR molecules have been correlated with spontaneous resolution of acute HCV GT1 infection (60) .
Future studies will be needed to determine whether this correlation with resolution is specific for only GT1 infection.
The majority of immunological studies on HCV, including this report, are conducted with antigens and peptides based on the GT1 sequence. Our data indicate that future studies on HCV-specific CD4+ and CD8+ T cell responses in acute, resolved, and chronic infection should take genotype into consideration. In particular, data might be more informative if genotype-specific reagents are used to define immunodominant epitopes in non-GT1 infection. Furthermore, a complete characterization of the cross-genotype reactivity of frequently detected genotype-specific CD4+ and CD8+ epitopes, should be performed.
Finally, our observation that none of the chronically infected individuals in this study (even those non-GT1 persons who showed responses in our assays) targeted previously identified, well conserved epitopes (e.g. P177 (aa1771-1790)), frequently detected in subjects with spontaneously resolved infection, is of significant importance with regards to future vaccine design (61) 
org From
In summary, we provide evidence at the single epitope level that a large percentage of HCV-specific CD4+ T cell responses detected in persons with persistent HCV viremia are not directed against the circulating virus, but are most likely "immunological scars" resulting from previous exposure to a heterologous virus strains. This study provides a comprehensive approach and analysis to extend previous findings based on case reports or studies using limited immunological assays. Our data strongly indicate an inherent difficulty in generating cross-genotype protection during natural HCV infection in a subset of subjects studied in this cohort. However, we have observed a lack of responses to a set of highly conserved CD4+ epitopes in chronic infection that may have significant implications for future vaccine development.
Acknowledgements
We thank foremost all subjects who generously enrolled into this study and the dedicated clinical research staff and nurses who helped to recruit them. We thank Michael Houghton and Kevin Crawford at Chiron Corporation for generous provision of the recombinant antigens. We thank Mark Brockman for critical discussion of the manuscript. This study was supported by the Howard Hughes Medical Institute (JSZW, BDW), Deutscher Akademischer Austauschdienst (JSZW), Deutsche Forschungsgemeinschaft (JT,TK), the National Institutes of Health grants U19-AI066345-02 (TMA, GL, AYK, LL and BDW), RO1-AI067926-01 (TMA) and RO1-AI031563-13 (BDW), and the American liver foundation (GL). JSZW designed and performed experiments, analyzed data, enrolled patients and wrote first draft. GL,AYK and AWL designed experiments and revised manuscript. BDW gave financial support designed experiments, wrote and revised manuscript. TMA, JT, TK, MN, AB performed and analyzed the sequencing experiments and revised the manuscript. AJ, BEN, SAL, VK perfomed experiments and revised the manuscript. AW, RTC, LL and CMcM enrolled patients, analyzed data and revised the manuscript.
Disclosures
The authors have no financial conflict of interest. (see table 2 ). This subject was infected with GT4 virus and showed a serological response to GT1 virus. We were able to cultivate peptide-specific lines a) by stimulating with GT1 based peptides, b) but not with autologous peptides (see materials and methods). c) dilution ICS assays performed on GT1-specific CD4+ T cell lines for all specificities confirm the lack of recognition of peptides representing the autologous sequence of subject C29 (see materials and methods) d) Ex vivo dilution Elispot data for two strong responses against p158 (1581-1600) and p180 (1801-1820) confirm that peptides based on GT1a sequence (black boxes) elicited much higher responses than peptides based on autologous GT2b sequence (grey triangles) in subject non-GT1 C35 (see materials and methods). peptides (black boxes) and autologous peptides (grey triangles) of subjects non-GT1 C29 and C35. a) spontaneous resolver subject R23 shared the restricting HLA DR1*1 alleles for epitope p158 (aa1581-1600) that was detected in subject C35. The GT1 specific peptdie sequence but not the GT2b-specific autologous variant of subject non-GT1 was recognized in dilution ICS experiments (see materials and methods). b) spontaneous resolver R1 shared the restricting HLA allele DRB1*11 for the previously described only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From epitope P227 (aa2271-2290) that was detected in subject non-GT1 C29. Here also, the GT1 peptide sequence, but not the GT4-specific, autologous variant of subject non-GT1 C29 was recognized. 
